HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
common myelogenous leukemia-associated antigen (CAMAL)
Also Known As:
CAMAL
; CAMAL-1
Networked:
11
relevant articles (
3
outcomes,
3
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Biological Factors: 2472
Biomarkers: 240291
Differentiation Antigens: 2082
Myelomonocytic Differentiation Antigens: 1
common myelogenous leukemia-associated antigen: 11
Antigens: 143924
Surface Antigens: 5813
Differentiation Antigens: 2082
Myelomonocytic Differentiation Antigens: 1
common myelogenous leukemia-associated antigen: 11
Related Diseases
1.
Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1988 - "
CAMAL: a new prognostic marker for remission in acute nonlymphoblastic leukemia.
"
01/01/1988 - "
ANLL patients at initial presentation whose CAMAL BM values increased or stayed the same post-chemotherapy had significantly (p less than 0.025) shorter remission lengths (x = 6.8 months, n = 24) than those whose CAMAL BM values decreased (x = 19.2 months, n = 10).
"
01/01/1984 - "
Evidence is presented that indicates that expression of the CAMAL antigen may represent continued underlying pathology in the acute myelogenous leukemia remission state.
"
01/01/1988 - "
We are ending the third year of an ongoing blind study designed to monitor the number of BM cells expressing the CAMAL protein (CAMAL BM value) in ANLL patients over the course of their disease.
"
02/01/1991 - "
A monoclonal antibody, CAMAL-1, has been previously shown to react specifically and at high frequencies with cells of patients with acute myelogenous leukemia (AML) and chronic granulocytic leukemia (CGL).
"
2.
Leukemia
12/01/1989 - "
Lack of or decreased responsiveness to inhibition by leukemia-derived CAMAL may facilitate dominance of the malignant clone over normal cells.
"
12/01/1989 - "
At similar concentrations (between 10 and 15 micrograms/ml), leukemia-derived CAMAL caused profound inhibition of normal colony growth in the myeloid progenitor cell assay but had no inhibitory effect on granulocyte-macrophage colony-forming unit (CFU-GM) growth from myeloid leukemia patients in active disease states.
"
09/01/1985 - "
Fusion products were selected for their ability to produce a leukemia-associated antigen (CAMAL) previously described.
"
08/01/1985 - "
Demonstration of a leukemia-associated antigen (CAMAL) in peripheral blood leucocytes of bone marrow transplant patients prior to relapse.
"
04/01/1994 - "
CAMAL (common antigen of myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood leucocytes of persons with myeloid leukemias.
"
3.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
08/01/1984 - "
Neither CAMAL-1 nor the rabbit antiserum bound appreciably to acute lymphocytic leukemia cells, normal bone marrow, or normal peripheral blood leukocytes.
"
08/01/1985 - "
Results of this study showed the following: of the 15 patients who remained in remission during the period of the study, 13 showed no abnormal increase in reactivity with CAMAL-1 (2 patients did show increased levels of reactivity over time); of the four patients relapsing but surviving within this period with ANLL, all showed elevated numbers of cells reactive with CAMAL-1 as long as 3 months prior to relapse (the two relapsing patients who had acute undifferentiated leukemia and acute lymphoblastic leukemia did not show elevations of CAMAL-1-reactive cells); of the 14 patients dying during this time of causes other than leukemia, none had elevated levels of CAMAL-1-reactive cells--and, of 4 patients dying in relapse, all had extremely elevated levels of CAMAL-1-reactive cells as long as 4 months prior to relapse.
"
4.
Lymphoid Leukemia
01/01/1984 - "
The specificity of the CAMAL-1 MAb has been established; most samples from patients with myelogenous leukemia (acute phase or remission and CGL chronic phase) show significantly increased numbers (greater than or equal to 1%) of CAMAL-expressing cells compared to those from normals or individuals with lymphoid leukemias.
"
5.
Myeloid Leukemia (Leukemia, Myelocytic)
12/01/1989 - "
These preliminary results indicated the myeloid leukemia cells possessed apparent differences in responsiveness to CAMAL-mediated regulation compared to normal cells.
"
12/01/1989 - "
At similar concentrations (between 10 and 15 micrograms/ml), leukemia-derived CAMAL caused profound inhibition of normal colony growth in the myeloid progenitor cell assay but had no inhibitory effect on granulocyte-macrophage colony-forming unit (CFU-GM) growth from myeloid leukemia patients in active disease states.
"
12/01/1989 - "
In this study, a common antigen in myeloid leukemia (CAMAL) has been shown to bind to normal leukocyte membranes.
"
01/01/1988 - "
p70 (CAMAL) has been shown to be a monomeric protein of Mr 70,000 and pI 7.2 and was also detectable in the myeloid leukemia cell lines HL60, KG1, K562 and U937, but not in the lymphocytic cell lines Molt-4, Hut-78 and CEM by immunoprecipitation from iodinated cell samples.
"
01/01/1988 - "
Both polyclonal and monoclonal (CAMAL-1) antibodies have been raised to p70 (CAMAL) and have been shown to react with both p70 and myeloid leukemia cell preparations.
"
Related Drugs and Biologics
1.
common myelogenous leukemia-associated antigen (CAMAL)
2.
Antigens
3.
Monoclonal Antibodies
4.
Proteins (Proteins, Gene)
5.
Antibodies
Related Therapies and Procedures
1.
Drug Therapy (Chemotherapy)